Vir Biotechnology has evolved into a dual-focus company with strong pharmaceutical partnerships and a fully enrolled Phase 3 program for hepatitis delta. The recent launch of Gilead’s bulevirtide is increasing hepatitis delta diagnosis rates, which benefits Vir’s upcoming ECLIPSE trials targeting patients who do not respond to bulevirtide. Additionally, a deal with Astellas validates Vir’s PRO-XTEN platform, bringing $335 million in upfront and near-term payments plus a premium equity investment. Despite trading near book value and having cash to operate into the second half of 2028, the market currently undervalues Vir’s pipeline beyond its cash position.
Vir Biotechnology stock is the subject, with Pluang market data providing context. For readers following the health sector, 39 of 100 US health stocks rose and 55 fell today. Notable movers include ADPT at USD 29.10 with a +2.07% change and 100% buy orders, XRAY at USD 9.46 with a +1.94% change and 100% buy orders, and FLNA at USD 0.84 with a -1.56% change and 73% buy orders. These figures are as of Sep 29, 2026 17:11 WIB.
Critical One Energy announced new drill results from its Howells Lake Antimony-Gold Project in Ontario, extending antimony mineralization 30 meters northeast of the East Zone and confirming additional gold zones beneath and in the West Zone. Highligh...
A crypto wallet transferred 1,445 Ether (ETH), valued at $3.91 million, from the Aave platform to Binance. This marks the wallet's first ETH deposit to an exchange since October 2025. Despite the transfer, the wallet still holds approximately $26.7 m...
Cyngn has secured a follow-on order from a Fortune 100 heavy equipment manufacturer to expand the use of its autonomous DriveMod Tugger for material handling at the customer's facility. This expansion supports a new production workflow, building on a...
Solana's price recovered from a dip below $100 in mid-September, driven by continuous net inflows into Solana spot ETFs over 11 weeks, signaling strong institutional demand. Analyst Ali Martinez highlights that Solana's network growth and shrinking e...
QuickSwap, a decentralized exchange known for its Polygon presence, has surpassed $700 million in total trading volume on Coinbase's Layer 2 network, Base, after launching there in May 2025. The platform steadily grew from $500 million in June 2026 t...
